• U.S.-based communications technology services provider FingerMotion recently announced a number of milestones in its drive to make its Sapientus big data arm a powerful driver of analytics in China’s billion-strong consumer marketplace
• The company has recently focused development efforts on a ready-to-launch mobile device protection plan similar to AppleCare that the company expects to be competitive in China
• The announcement regarding Sapientus renews expectations that it will evolve beyond its core SMS and mobile top-up services, building on unique partnerships with China’s telecommunication giants and other global corporations
• The Sapientus updates include news that FingerMotion has reached a new agreement with global reinsurance company Pacific Life Re to provide risk-rating capabilities, and that Sapientus’ analytical capabilities have been strengthened

Paying attention to credit score ratings has become a common part of the U.S. consumer’s mindset, particularly during economic downswings when lending interest rates are high and the risks of unemployment are higher (https://ibn.fm/hLNs5). During recent years, mobile technology services provider FingerMotion (NASDAQ: FNGR) has built credit analyzing prowess on its framework of cell phone minutes top-up servicing and SMS texting-related products, recognizing a world of potential in China’s burgeoning consumer market and FingerMotion recently announced upgrades to its credit data technologies to meet the need. China is the most populated country in the world, home to about 1 in every 5 of the earth’s inhabitants, and its growing middle-class workforce is driving a huge economic engine. That engine is largely founded in international trade, amounting to about half its GDP. And its share of GDP in relation to global output rose from 2.5 percent to 17.2 percent during the 35 years between 1980 and 2015. In the process, retail sales reach into the trillions of dollars (https://ibn.fm/rLMRs). But China’s insurance risk and credit risk evaluation infrastructure is still underdeveloped, creating a particular need for big data solutions that can help companies analyze consumer behaviors and create predictive algorithms. U.S.-based FingerMotion’s establishment of partner networks in China that include telecommunications giants China Unicom and China Mobile have made it attractive to other corporate giants as it has built its big data product Sapientus over the past year to serve as a credit risk analysis technology. Global life reinsurance company Pacific Life Re was the first to contract with FingerMotion for consumer risk data to serve Pacific Life’s Re-insurance division in China, and more recently a large New York Stock Exchange-listed insurance company partnered with FingerMotion in its drive to break into the Chinese market. On Aug. 24, FingerMotion announced updates to its Sapientus division, including a new agreement with Pacific Life Re to take that collaboration forward into a new phase, an upgrade of Sapientus’ algorithms with “more elaborative auxiliary data” to strengthen the quality of its analytical results, and the rollout of FingerMotion’s risk-rating API for commercial use. Sapientus has successfully obtained seven patents from the National Copyright Administration of China (“NCAC”) for its proprietary technologies. “Our risk rating API platform is the foundational end product built upon collaborative research conducted with our core partners over the course of the past year,” FingerMotion CEO Martin Shen stated (https://ibn.fm/aSVP1). “We look forward to leveraging this significant achievement and look to realize many more innovation possibilities across the commercialization spectrum.” For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• CNS Pharmaceuticals, a Texas-based cancer drug developer, is advancing testing efforts for its lead drug candidates in the fight against glioblastoma (“GBM”) and other tumors
• Glioblastoma is an aggressive brain cancer that claims the lives of more than 10,000 Americans each year, with more victims worldwide, and it has no known cure
• CNS Pharmaceuticals’ efforts rely on establishing the safety and effectiveness of its lead candidate, Berubicin
• Berubicin is an anthracycline (chemotherapy agent) with the apparent ability to cross the blood-brain barrier to attack central nervous system tumors, which grants it a unique status among anthracyclines
• CNS has shown evidence of slowing disease progression among GBM patients and in some instances even shrinking tumor size, and is currently enrolling volunteers in a trial that compares Berubicin against chemotherapeutic agent Lomustine

Bit by bit, medical researchers have been improving treatment options for an aggressive, incurable brain cancer that kills an estimated 10,000-plus people in the United States each year, and more worldwide. Glioblastoma (“GBM”) is generally treated with radiochemotherapy and surgical tumor removal once the cancer is discovered, usually after the sudden onset of headaches and nausea. But eventually, nearly every tumor returns after the initial course of treatment, and the recurrent cancers are increasingly difficult to attack without causing more extreme harm to the patient. Most patients pass away from these tumors 12 to 15 months after first diagnosis (https://ibn.fm/4Qrgy) and only 10 percent reach a five-year survival. Because of glioblastoma’s recognition as an unmet medical need — a currently incurable illness, or one with very ineffective treatments — the field of research to combat it has been competitive. Most recently, investigators at Tel Aviv University (“TAU”) reported success at starving the brain tumors in mice by dealing with the cells surrounding the tumors (https://ibn.fm/nWzO6), with implications for other drug products that might potentially be used against GBM. Biopharmaceutical innovator CNS Pharmaceuticals (NASDAQ: CNSP) is currently conducting a potentially pivotal global Phase 2 clinical trial in humans to test the effectiveness of its anti-GBM drug candidate — Berubicin — after Berubicin testing resulted in a notable success with evidence of improved survival among a dozen safety trial participants recruited by drug’s original developer over 15 years ago. One patient had a cancer-free response and continues to survive, another experienced a partial response that lasted for 12 weeks and nine patients experienced a stable disease response for over six weeks (https://ibn.fm/wVPVx). The current clinical trial is enrolling patients in up to 54 sites selected in the United States, Italy, France, Spain and Switzerland to compare Berubicin’s response against the standard-of-care chemotherapy agent Lomustine. Twenty-three of those sites are open and operating already. CNS Pharmaceutical recently held its annual stockholder meeting to re-elect officers and conduct other business (https://ibn.fm/sCWx3), following on the company’s announcement of its Q2 performance that showed a general reduction of expenses thanks largely to drug development timing (https://ibn.fm/r2qFY). Among other news in CNS Pharmaceutical’s report, the company indicated its secondary drug portfolio WP1244 — an anthracycline-based substance that is being evaluated for treatment of brain cancers, pancreatic, ovarian, and lymphomas — has produced a new derivative identified as WP1874 with enhanced solubility compared to WP1244. “Going forward, WP1874 will be the primary focus in our development efforts of the WP1244 portfolio,” the company stated. “CNS Pharmaceuticals is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.” CNS anticipates filing for Investigational New Drug (“IND”) recognition for WP1874 in the coming year. Berubicin has already been granted Fast Track and Orphan Drug designations by the U.S. Food and Drug Administration (“FDA”). For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Exciting times are ahead for solar as US Consumers seem hungry for more renewable energy and government introduces the largest-ever US climate investment
• As energy efficiency becomes priority, this game-changing legislation incentivizes consumers to invest in clean energy upgrades such as solar and wind; demand expected to rise and stay robust over the coming years
• GeoSolar stands ready to respond to this burgeoning market need with its unique system that integrates clean energy technologies such as solar power, geothermal ground-sourced energy and more

Without a doubt, modern consumers seek to lead more sustainable lifestyles and play a meaningful role in the fight for a healthier planet. But as energy prices soar and the cost-of-living balloons, they are also prompted by monetary factors to act toward energy-efficient living. Companies like Colorado-based GeoSolar Technologies (“GST”) appear well placed to ride the new wave of the push for a greener economy as energy transition becomes one of the biggest areas of consideration for consumers, developers, businesses and governments alike. As much as global warming is a high-level global problem requiring a concerted effort of multiple stakeholders worldwide, today’s consumers are ready to rise to the challenge on an individual level, eager to find ways to make their own contributions toward a greener future. A recent survey shows that almost 72% of respondents consider reducing their carbon footprint as nothing less than a personal priority. Over half of them (55%) said they “place importance” on their homes becoming net-zero (https://ibn.fm/WG4W9). The US government is working to make these admirable aspirations possible, offering a myriad of generous incentives for consumers to make a shift to alternative energies. The new landmark legislation known as the Inflation Reduction Act promises to deliver significant savings by allowing hefty tax rebates for green technologies. With nearly $370 billion allocated to green and energy-related projects and incentives, the bill is lauded as “the largest investment ever in combating the existential crisis of climate change.” It is designed to reduce energy costs by directing support to renewable projects, including wind and solar, that can offer a less price volatile source of electricity compared to conventional ones such as gas, coal, and oil. Some developers believe that consumers can get tax credits amounting to as much as 60% of a project’s cost (https://ibn.fm/SB6Ds). The rise of environmental awareness, coupled with swelling energy bills, is expected to spur more household demand for green energy. Solar tax credits have not only been extended until 2032 but have also increased from 26% to 30%. The interest this legislation has generated so far is reportedly off the charts. Installers of solar equipment expect the demand for their services to surge – apparently, enough to keep them busy over the next few years. As the creator of the SmartGreen(R) home system that harnesses energy from the earth and sun to power homes and automobiles, GeoSolar Technologies appears well-placed to capitalize on these changes as a growing number of homeowners take the plunge and join the renewables bandwagon. Renewable technologies can offer unprecedented benefits. For example, once homeowners recoup their solar investment, the electricity this technology generates could practically be free apart from maintenance and service fees for connecting to the power grid. It is estimated that an average house could save from $10,000 to $30,000 over the span of 25 to 30 years, which is the typical shelf life of a solar panel system (https://ibn.fm/u0OZf). With soaring costs of living, managing energy costs are the key driver urging consumers to invest in solutions that put them in control over how energy is produced, stored, and distributed in their homes. They seek green solutions that fulfill their needs both in terms of sustainability and energy bills. With new technologies such as SmartGreen(R) home system, they should be able to do good for the planet and their wallet without compromising on their comfort. For more information, visit the company’s website at www.GeoSolarPlus.com. NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• Cepton, in collaboration with ZKW Group GmbH, plans to showcase its Nova lidar headlamp integration into a ZKW heavy-duty truck headlamp at the IAA Transportation Conference (Sept. 20-25, 2022)
• Nova is an award-winning, miniature, wide field of view, near-range lidar sensor that provides high resolution 3D imaging in a compact form factor
• Nova integrates seamlessly around vehicles to provide 360-degree perception boosting blind spot detection, which is becoming a mandated vehicle safety feature

The success of autonomous vehicles (“AV”) and advanced driver assistance systems (“ADAS”) hinges on technologies that make 360-degree intelligent perception possible. Cepton (NASDAQ: CPTN), a Silicon Valley innovator of lidar-based solutions for the automotive (“ADAS/AV”) and smart technology spaces, is leading the way with Nova, an award-winning short-range lidar solution that’s lightweight, flexible, energy-efficient, and easy to integrate into passenger and commercial vehicles. CPTN recently announced the company’s collaboration with ZKW Group GmbH to demonstrate Nova at the upcoming IAA Transportation conference from September 20-25, 2022 (https://ibn.fm/rB5BJ). “We are excited to showcase our collaboration with ZKW at this year’s IAA event,” said Dr. Jun Pei, Cepton’s CEO and co-founder. “ZKW is a leading innovator of automotive lighting technologies and working with the ZKW team allows Cepton to demonstrate how our lidars are optimized for use in everyday vehicles.” Cepton’s exhibit will demonstrate how Nova helps eliminate blind spots and create a “safety cocoon” around the vehicle by combining high-resolution, superior field of view coverage in all directions. Nova’s super-compact form additionally features flexible options to integrate discretely in various locations around the vehicle to provide complete 360-degree perception that accurately detects objects from every direction, including pedestrians, bicycles, and low-proximity obstacles on the road surface. “Being able to be seamlessly integrated into locations like headlamps is a key factor of the outstanding scalability of Cepton lidar,” said Dr. Pei. “With that, we aim to bring lidar’s safety benefits to everyone on the road – drivers, passengers, and road users alike – while helping advance the future of autonomous mobility.” During the IAA Transportation conference exhibit, Nova will be integrated into a heavy-duty truck headlamp provided by ZKW. The headlamp integration solution features sensor protection and a cleaning mechanism that facilitates user maintenance. “For us as an innovative supplier of premium lighting systems, it is very important to engage with the right technologies,” said Dr. Wilhelm Steger, CEO of the ZKW Group. “That’s why we are constantly on the lookout for competent partners – like here in the field of lidar with Cepton.” Cepton’s patented lidar technology enables an optimal balance between performance, reliability, and cost efficiency. The company offers a comprehensive portfolio of lidar solutions, including lidar sensors for near to ultra-long-range applications, and intelligent perception solutions that can be applied to smart cities, smart spaces, and smart industrial applications. For more information, visit the company’s website at www.Cepton.com. NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

• Global cannabis brand-builder Flora Growth recently named a former Amazon financial executive as its new CFO
• Elshad Garayev will work with outgoing CFO Lee Leiderman to ensure a smooth transition of responsibility amid finalization of Flora’s mid-year financial filing with the SEC
• Flora Growth is headquartered in Canada with cultivation operations centered in Colombia, where recent government administrations have opened regulatory processes for exporting cannabis derivatives for the health and wellness markets
• The company continues to expand its operations internationally for sales in the UK and Europe generally, Australia, and throughout the Americas

Global cannabis brand-builder Flora Growth (NASDAQ: FLGC) has steadily built an aggressive international expansion of its Colombia-based cultivation operation during the past year and a half, launching exports to countries such as Mexico and Spain and opening doors to the United Kingdom and the United States. Flora Growth, which is headquartered in Ontario, Canada, and is establishing offices in the United States, also anticipates end user markets in Australia, various countries in Latin America, as well as in Europe and Asia. Flora Growth has recently named a former financial executive at Amazon, Boeing, BP, and RPK Capital, as the new chief financial officer, tasked with overseeing financial governance and effective cash position strategy as Flora moves towards quarterly financial reporting and solidifies its global growth. The company stated that Elshad Garayev will initially serve as vice president of finance while working with the outgoing CFO, Lee Leiderman, through a transition period culminating with Flora’s filing of its mid-year financial results with the Securities and Exchange Commission. Once that filing is completed, Garayev will take over as CFO on the following business day and Leiderman will move into an advisory role to help ensure a smooth continuation of operations, according to the July 11 announcement (https://ibn.fm/k94cm). “Mr. Garayev is a deeply talented and experienced individual, and I am thrilled to welcome him to the Flora team at this exciting time in the company’s evolution,” Chairman and CEO Luis Merchan stated in the announcement. “As Flora seeks to establish itself as a global leader in cannabis, adding someone of his caliber will further strengthen our position.” In addition, the company appointed JPMorgan Chase alum Brandon Konigsberg to their board of directors, and as a member of the audit and comp committees. “The addition of Mr. Konigsberg to our Board is further testament to our ongoing commitment to fiscal discipline and sound governance. He brings with him exceptional experience in the fields of finance and operations and will assist in helping our organization achieve rapid financial growth and maximize our shareholder value,” said Luis Merchan, Flora’s Chairman and CEO (https://ibn.fm/QokvH). “We are pleased to welcome Mr. Konigsberg as a valued member of our team and look forward to his contributions.” This year, the company has acquired 100 percent equity interests in Just Brands LLC and High Roller Private Label LLC as it has advanced its strategic position. The acquisitions brought the JustCBD brand into Flora’s stable (https://ibn.fm/Tvlz4), which is expected to in turn help the company expand its operational footprint in Europe and the United Kingdom through JustCBD’s 79 products authorized by the UK’s novel foods standards agency (https://ibn.fm/1cQO5). The company’s announcement states its JustCBD gummies and tinctures will begin selling on Amazon’s UK web portal this summer. Flora’s outdoor cannabis cultivation facilities in central Colombia grant it prime positioning for product growth in a fertile zone that is accessible to an experienced grower labor force. The company uses natural, cost-effective cultivation practices to supply cannabis derivatives to its commercial, house of brands, and life sciences divisions, which together form a design-led collective of plant-based wellness and lifestyle brands. For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• Medical company Odyssey Health has received approval from the Safety Review Committee to start Cohort II of its Phase I trial’s Multiday Ascending Dosing (“MAD”) stage
• The approval follows evidence that Odyssey’s PRV-002 concussion drug candidate was safe and well-tolerated, as seen in Cohort I of the MAD stage
• The pharmacokinetic analysis also supports the hypothesis that more drug is getting to the brain itself, backing the company’s use of its patent-pending breath-propelled intranasal drug administration device
• The company believes that the intranasal drug/delivery combination will be instrumental in the success of the PRV-002 drug candidate in planned Phase II/III trials

Odyssey Health (OTC: ODYY), a medical company focused on unique, life-saving medical products that offer clinical advantages to unmet clinical needs, has received approval from the Safety Review Committee to proceed with dosing and evaluation of Cohort II volunteers of the Multiday Ascending Dosing (“MAD”) stage of its ongoing Phase I clinical trial. Aimed at evaluating the safety and tolerability of the company’s novel drug candidate to treat concussion, PRV-002, the Phase I study involves healthy human volunteers who receive a dose of the drug. “After reviewing the data from MAD Cohort I, I have strong confidence that PRV-002 will continue to show safety during the final, high-dose MAD portion of the Phase I clinical trial. We have unanimously approved the start of MAD Cohort II,” Dallas Hack, MD, a member of the Safety Review Committee, told Neurology Live (https://ibn.fm/xftAb). In an August 10 news release, Odyssey announced the completion and safety findings from Cohort I, showing that PRV-002 was safe and well tolerated. The Cohort 1 of the MAD stage included eight healthy human subjects who received a low dose of intranasal PRV-002 for five consecutive days, followed by evaluations for abnormal responses. No severe adverse events were observed (https://ibn.fm/cXbkJ). Additionally, pharmacokinetic (“PK”) analysis of the data from the first Cohort provided new information that, Hack underlined, support the hypothesis that more drug is getting to the brain itself rather than the circulation. The PK analysis evidenced a direct linear relationship between drug dosing concentration and blood plasma levels. This means that the drug dosing concentration (amount of drug in the body) increased with a rise in blood plasma levels (concentration of the drug in the plasma). The PK analysis further showed that the blood levels of the intranasally administered active drug were substantially lower on average than what would ordinarily be expected with other routes of administration. Moreover, the evaluations did not reveal any appreciable accumulation of PRV-002 with consecutive day treatments, and the MAD did not alter blood samples. “The overall low levels of PRV-002 in the blood support the hypothesis that more drug is getting to the brain itself when administered with the intranasal device. If this turns out to be the case, not only can the targeted effects of the drug be more efficacious, but the drug will also likely have fewer potential side effects,” Hack continued. Hacks’ observation is consistent with separate comments by Odyssey Health CEO Michael Redmond and the company’s Head of Drug Development, Dr. Jacob VanLandingham. In an interview with the RedChip Companies published on YouTube (https://ibn.fm/COh15), Redmond said the breath-propelled intranasal device, which delivers a powderized drug through the upper chambers of the nasal cavity, enables the drug to cross the blood-brain barrier within five minutes, following which it “spreads out throughout the brain within 30 minutes and reverses the effects of a concussion.” On his part, Dr. VanLandingham believes intranasal brain-targeting will be instrumental in the success of PRV-002 should it be efficacious for concussed patients in the planned Phase II/III trials. The Phase II study is intended to evaluate the efficacy of PRV-002 in concussed patients. “So far, the intranasal drug/device combination has functioned nicely and has been well-tolerated in the clinical setting,” concluded Dr. VanLandingham. Odyssey is now looking to commence its Phase II clinical trial subject to the submission of the Phase I trial results and approval by, among other relevant regulatory bodies, the U.S. Food and Drug Administration (“FDA”). To that end, the company is currently scouting for clinical sites in collaboration with the U.S. military and developing the Phase II Investigator’s Brochure for the Phase II trial. For more information, visit the company’s website at www.OdysseyHealthInc.com. NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY

• Todd Michaels, Correlate’s Founder, President, and CEO, appeared on the latest episode of the Bell2Bell Podcast, where he talked about the company’s background, its achievements so far, and what lies ahead
• Mr. Michaels highlighted the opportunity in solar power generation, acknowledging that by 2050, it should account for around 40% of the actual overall capacity of energy generation in North America
• He also cited the Inflation Reduction Act, which adds incentives that are expected to help drive a significant leap forward for Correlate
• Mr. Michaels also highlighted the steps made by the company so far in 2022, citing the uplisting on the Nasdaq and an agreement to acquire the leading efficiency and commercial solar business in the state of Hawaii
• He was keen to point out that the company’s future looks bright and even maintained potential revenue growth projections for the subsequent quarters of the 2022 financial year

While appearing on the latest episode Bell2Bell Podcast, Correlate Infrastructure Partners (OTCQB: CIPI) Founder, President, and Chief Executive Officer (“CEO”), Todd Michaels, expressed his optimism about the company’s future, while highlighting its achievements so far, and the opportunities that lay ahead (https://ibn.fm/D5ALR). Mr. Michaels was keen to share the company’s background, noting some of its critical commercial brands, mainly Solar Site Design and Correlate. He also highlighted the company’s plans to add technologies and companies to its portfolio in a move that looks to further scale the business through technology enablement and automation. Correlate has carved out a significant market in North America, offering solar energy solutions, energy storage, and even electric vehicle infrastructure. However, it acknowledges that tremendous opportunity lies in solar power generation, particularly given projections that by 2050, it will account for around 40% of the actual overall capacity of energy generation. “The solutions that we deploy through those programs and subsidiaries in different parts of the country are things like solar, [energy] storage, energy efficiency and electric vehicle infrastructure,” noted Mr. Michaels. “We do that today in residential, commercial and industrial [applications], along with the burgeoning space of community-scale projects,” he added. On August 15, 2022, the Inflation Reduction Act was signed, in what marks the country’s biggest climate package. The goal of the law is to cut domestic greenhouse emissions while also lowering prescription drug prices. From an emissions standpoint, this presents an opportunity for Correlate, mainly since it is already a key player in the clean energy space (https://ibn.fm/7hMnp). Mr. Michaels acknowledged the significance of this law, noting that “It has never been a better time for our business”, and indicating “We were on a great trajectory growing organically, but the incentives from the Inflation Reduction Act are going to be a major leap forward for our business,” he added. So far in 2022, Correlate has made significant moves to grow its brand equity and create value for its shareholders. In June, it applied for uplisting on the Nasdaq, and before that, it executed an agreement to acquire the leading efficiency and commercial solar business in Hawaii. Its projects are only getting bigger, its client pool is growing, and these, according to Mr. Michaels, are all setting the company up for further growth as time progresses. Throughout the podcast, Mr. Michaels expressed his optimism about the company’s performance while also attributing its current success to the team behind the scenes. More importantly, Mr. Michaels showed the company’s commitment to clean energy solutions and creating value for its shareholders, factors that have shaped its decision-making, and its trajectory so far. For company information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• CNS reported a decrease in losses from $3.8 million in Q2 2021 to $3.6 million in Q2 2022, as well as a drop in research and development expenses from $2.7 million to $2.2 million, with an increase in general and administrative expenses from $1.1 million to $1.3 million
• The company closed the quarter with $9.0 million in cash, and a working capital of approximately $10.3 million which, it is confident, will fund its operations into the 2023 calendar year
• CNS looks to continue site initiations across the U.S., Italy, France, Spain, and Switzerland, while also pushing for regulatory and ethics approvals specifically for Italy
• It maintains that its focus and priorities remain on advancing its clinical development program for Berubicin for the treatment of GBM

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology enterprise focusing on the development of novel treatments for brain tumors, just released its financial results for the second quarter (“Q2”) of the 2022 fiscal year ended June 30, 2022. Of note was a notable performance improvement, with losses dropping from $3.8 million during the same period in 2021 to $3.6 million in 2022. This improvement was mainly attributed to the decreases in the timing of drug development expenses (https://ibn.fm/TWnMh). Research and development expenses also dropped from $2.7 million in Q2 2021 to $2.2 million for Q2 2022. On the other hand, general and administrative expenses saw a bump to $1.3 million, up from $1.1 million during the same period in 2021. This was linked to overall growth in employee compensation, taxes, and legal and professional fees, all of which were offset by decreases in stock-based compensation and other expenses. CNS kicked off Q3 2022 with approximately $9 million in cash, and working capital of approximately $10.3 million, which, it is confident, will fund its operations into the 2023 calendar year. Currently, the company is exploring the full potential of its lead product candidate, Berubicin. Results from clinical studies over the last six months have proven fruitful, even as the company continues to work toward approval by the United States Food and Drug Administration (“FDA”). “Within the past 6 months alone, we have executed on a number of clinical and operational advancements including expanding our global presence with clinical approvals in Spain, France, and Switzerland to drive patient enrollment forward, as well as expanding eligibility for patients to participate in our potentially pivotal study of Berubicin for the treatment of Glioblastoma Multiforme (‘GBM’) with our recently amended protocol, which was approved by the FDA, Swissmedic, National Agency for the Safety of Medicine and Health Products (‘ANSM’) Competent Authority and Corresponding European ethics committees,” noted John Climaco, CNS’ Chief Executive Officer (“CEO”). Even with the achievements thus far, CNS remains committed to advancing its research even further, taking advantage of the previously granted Fast Track Designation for Berubicin by the FDA. In addition, the company has received Orphan Drug Designation from the FDA, providing seven years of marketing exclusivity upon approval of a New Drug Application (“NDA”). CNS is looking to continue site initiations across the United States, Italy, France, Spain, and Switzerland while pushing for regulatory and ethics approvals specifically for Italy. It also seeks to commence patient enrollment across its European clinical sites even as it works towards the interim analysis of the trial when 30-50% of the total expected patients have been on study for at least six months. This, its management argues, defines the company’s focus and commitment to creating value for its shareholders. “Our focus and priorities remain on advancing our clinical development program for Berubicin to ultimately bring a meaningful treatment to GBM patients, families and clinicians, who currently have extremely limited and often ineffective treatment options,” noted Mr. Climaco. CNS continues to advance the development of its lead product candidate and its overall drug technology portfolio. It is indicative of its commitment to offering a solution to patients dealing with GBM, their families, and clinicians at the forefront of offering the necessary treatment services to these patients. More importantly, it indicates the company’s commitment to creating shareholder value and living up to shareholder expectations. Its management is confident that a significant performance improvement is imminent with the framework laid down so far. For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Martin Shen, FingerMotion’s CEO, noted the company’s shift in focus to pushing gross margins higher for the 2022 calendar year
• This has shaped the company’s initiatives that have seen the addition of the mobile device protection service for the Chinese market
• Since launching the service, FingerMotion has received $4 million in funding from Lind Global Fund II, LP, and is confident that this investment will yield the highest return, strengthen the company’s balance sheet, and enable it to experience transformational revenue growth over the next 12-24 months
• Mr. Shen has maintained that the current revenue is just “the tip of the iceberg,” as it banks on the relationships forged with key players in the Chinese market, in addition to benefiting from a first-mover advantage
• Recent developments by the company show its commitment to offering unique services to the market, creating shareholder value, its understanding of the Chinese market, and the competence of its management

Earlier in the year, Martin Shen, the Chief Executive Officer (“CEO”) of FingerMotion (NASDAQ: FNGR), an evolving technology company with a core competency in mobile payment and recharge platform solutions in China, noted that the company would shift its focus for the 2022 calendar year. In addition, he noted that its initiatives would push gross margins higher, mainly building on the momentum gained so far in terms of performance. “One of our key initiatives is to keep pushing gross margins higher, and we have been quite successful by optimizing our product offerings,” he noted (https://ibn.fm/e68dO). FingerMotion previously focused on four company offerings: telecommunications products and services, SMS and MMS services, big data insights, and Rich Communication Services (“RCS”). However, it recently sought to further diversify this list by venturing into China’s mobile device protection business. Since launching the service, FingerMotion has closed a funding agreement to the tune of $4 million with Lind Global Fund II, LP, an investment fund managed by The Lind Partners, a New York-based institutional fund manager. Mr. Shen is confident that this investment, channeled into the mobile device protection business, will yield the highest capital investment return within the shortest time, indicating that “the company’s highest priority initiative is the full-scale nationwide rollout of its mobile device protection business in China,” allowing the company to “experience transformational revenue growth over the next 12-24 months.” (https://ibn.fm/84oU3). FingerMotion has, since its inception, never shied away from exploring new territories and trying out new revenue-generating initiatives. Having started with facilitating online payments, the company is set on its goal to serve over a billion users in the Chinese market, eventually expanding its model to other regional markets. This recent move has shown the company’s commitment to creating shareholder value, its understanding of the Chinese market, and recognition of its potential to be a leader in this market and beyond. Mr. Shen has even expressed cautious optimism on the company’s performance, noting that the 37% revenue growth during the past year is nothing but sustainable, mainly due to the company’s recent additions, specifically the device protection program. “I think our revenue right now is really just the tip of the iceberg,” Mr. Shen noted (https://ibn.fm/tFtDE). FingerMotion also banks on the amount of data it has acquired over the years and the relationships it has forged with key players in the Chinese market. In addition, it benefits from a first-mover advantage in consumer data analysis and payment processing within China, factors that set the company apart from other players in the industry. Mr. Shen acknowledges that this is integral to pushing the company’s gross margins higher for the 2022 calendar year. Shareholders and customers can expect a lot from FingerMotion going forward, and for a good reason. The company has shown commitment to offering unique services in the market and creating an environment where shareholders draw value from every decision made. This speaks to its understanding of the intricacies of the Chinese market and the competence of Mr. Shen’s team, which has been primarily responsible for the company’s success thus far. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• President Biden has signed his signature climate change legislation into law, providing hundreds of billions of dollars to spearhead decarbonization efforts
• Homeowners are highly incentivized to switch to perform energy audits and switch efficient electric technologies, the exact area of focus of GeoSolar Technologies
• GeoSolar Technologies SmartGreen(TM) systems use geothermal and solar technologies that align with government incentives to maximize home efficiency

On August 16th, President Joe Biden signed the Inflation Reduction Act (“IRA”) into law, earmarking some $369 billion in funding for energy and climate projects with the goal or reaching a 40 percent reduction in carbon dioxide emissions by 2030 compared to 2005 levels. Amongst other things, the new law includes a host of incentives for consumers to transition to renewable energy, which is a benefit to companies like GeoSolar Technologies (“GST”) that specialize in packages focused on energy efficient homes. The aptly named Denver-based company uses geothermal systems to capitalize on the near constant temperature of the ground for heating and cooling and solar panels on the roof to harness power from the sun’s rays to generate a house’s electricity needs. In between the roof and the footings, GeoSolar provides all the necessary products in its SmartGreen(TM) program to maximize a home’s efficiency, including new insulation, floor loops, high volume heat/air pump, LED lighting, and air purification system, none of which utilize fossil fuels. SmartGreen(TM) is applicable in commercial and residential properties, whether existing (retrofit) or new construction. The upstart, which is raising capital via a Regulation A+ offering, has installed its home technology on multiple test homes in Colorado, scoring at the upper echelon of the industry-standard Home Energy Ratings System (“HERS”) index. The company claims that SmartGreen(TM) technology reduces or eliminates utility bills and cuts carbon emissions by 8 tons a year. GeoSolar’s quest to achieve carbon-free living by 2035 squares with President Biden’s signature legislation. IRA extends (or replaces) incentives and rebate programs and allocates capital for 950 million solar panels, 120,000 wind turbines, and 2,300 grid-scale battery plants. Homeowners can benefit to the tune of $14,000 in home energy rebates for installing electric appliances. Starting January 1, 2023, the Energy Efficient Home Improvement Credit replaces the Nonbusiness Energy Property credit. The new law provides a tax credit equal to 30 percent of the costs for all eligible home improvements made during 2023, including things such as electric panels, heat pumps, and energy audits, all things that GeoSolar provides. Further, consumers are goosed to buy an electric vehicle, via a $7,500 tax incentive for a new EV or $4,000 for a used one. Each SmartGreen(TM) system includes a new EV charging station installed in the garage and powered by the rooftop photovoltaic solar panels. According to an August brief from electrification nonprofit Rewiring America, the savings can add up to lifechanging money. The organization estimates that a household switching fossil fuel dependence to an electric heat pump, heat pump water heater, solar panels, and one electric vehicle would save $1,800 annually. Using the savings to further electrify the house will result in compounding savings, which Rewiring America says can grow into $140,000 after 25 years. When Biden opines on how IRA fights inflation and gives everyday people extra disposable income, this is part of the rationale. Electrek provides a comprehensive view on how IRA and electrification to cut our dependence on the gas and oil industry can help dull the effect of GDP-based recessions. It’s going to take leaders in the decarbonization movement to make this happen. For more information, visit the company’s website at www.GeoSolarPlus.com. NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST